| scholarly article | Q13442814 |
| P2093 | author name string | D D Ho | |
| M G Sarngadharan | |||
| M S Hirsch | |||
| R T Schooley | |||
| R C Kennedy | |||
| T C Chanh | |||
| T R Rota | |||
| V L Sato | |||
| P2860 | cites work | Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS) | Q22242256 |
| Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody | Q27485050 | ||
| Complete nucleotide sequence of the AIDS virus, HTLV-III | Q28259080 | ||
| Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS | Q28262859 | ||
| The role of mononuclear phagocytes in HTLV-III/LAV infection | Q29618676 | ||
| Application of a modified computer algorithm in determining potential antigenic determinants associated with the AIDS virus glycoprotein. | Q30355339 | ||
| Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. | Q30355613 | ||
| Induction of anti-HIV neutralizing antibodies by synthetic peptides | Q33880796 | ||
| Antibodies Reactive with Human T-Lymphotropic Retroviruses (HTLV-III) in the Serum of Patients with AIDS | Q34055350 | ||
| Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. | Q34382153 | ||
| Infection of monocyte/macrophages by human T lymphotropic virus type III. | Q34579117 | ||
| Immunological properties of the Gag protein p24 of the acquired immunodeficiency syndrome retrovirus (human T-cell leukemia virus type III). | Q37688961 | ||
| HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex | Q41379235 | ||
| Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus | Q43563098 | ||
| HTLV-III in the Semen and Blood of a Healthy Homosexual Man | Q43891747 | ||
| Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients | Q44255828 | ||
| Use of anhydrous hydrogen fluoride in peptide synthesis. I. Behavior of various protective groups in anhydrous hydrogen fluoride. | Q44420232 | ||
| Antibody to lymphadenopathy-associated virus in AIDS. | Q44502165 | ||
| Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein | Q44509170 | ||
| Genetic variation in AIDS viruses | Q44811995 | ||
| Immunoprevention of Friend virus-induced erythroleukemia by vaccination with viral envelope glycoprotein complexes | Q45793636 | ||
| In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). | Q45836762 | ||
| Genomic diversity of human T-lymphotropic virus type III (HTLV-III). | Q45838359 | ||
| Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome | Q48427365 | ||
| Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein. | Q55244204 | ||
| Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. | Q55244821 | ||
| Immunological properties of HTLV-III antigens recognized by sera of patients with AIDS and AIDS-related complex and of asymptomatic carriers of HTLV-III infection. | Q55244902 | ||
| Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells. | Q55244996 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 2024-2028 | |
| P577 | publication date | 1987-06-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins | |
| P478 | volume | 61 |
| Q36821056 | A predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gp120. |
| Q39545387 | A single amino acid substitution in the transmembrane envelope glycoprotein of feline immunodeficiency virus alters cellular tropism |
| Q37603996 | Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody |
| Q71678992 | Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activity |
| Q36634341 | Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum |
| Q33571605 | Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120 |
| Q36641374 | Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans |
| Q36811962 | Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees |
| Q28368240 | Assays to detect and characterize human immunodeficiency virus type 1 (HIV-1) receptor antagonists, compounds that inhibit binding of the HIV-1 surface glycoprotein, gp120, to the CD4 receptor on human T lymphocytes |
| Q40130078 | B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus |
| Q36687749 | Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses |
| Q36695580 | Blocking of human immunodeficiency virus infection depends on cell density and viral stock age |
| Q36784444 | CD4 immunoadhesin, but not recombinant soluble CD4, blocks syncytium formation by human immunodeficiency virus type 2-infected lymphoid cells |
| Q36806704 | CD4-independent, productive human immunodeficiency virus type 1 infection of hepatoma cell lines in vitro |
| Q36802755 | CD4-independent, productive infection of a neuronal cell line by human immunodeficiency virus type 1 |
| Q67899864 | Cellular and humoral antigenic epitopes in HIV and SIV |
| Q33261431 | Characterization and large production of human monoclonal antibodies against the HIV-1 envelope |
| Q36869394 | Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope |
| Q36831159 | Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4. |
| Q44917676 | Characterization of monoclonal antibodies identifying type and strain-specific epitopes of human immunodeficiency virus type 1 |
| Q35607085 | Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody |
| Q39875549 | Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection. |
| Q40062738 | Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody |
| Q36231815 | Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis |
| Q55241675 | Definition of an immunodominant T cell epitope contained in the envelope gp41 sequence of HIV-1 |
| Q36690394 | Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies |
| Q34750051 | Detailed topology mapping reveals substantial exposure of the "cytoplasmic" C-terminal tail (CTT) sequences in HIV-1 Env proteins at the cell surface |
| Q40113553 | Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis. |
| Q41296024 | Drug delivery issues in vaccine development |
| Q36872993 | Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1 |
| Q36812220 | Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. |
| Q45874261 | Enhanced proliferative cellular responses to HIV-1 V3 peptide and gp120 following immunization with V3:Ty virus-like particles |
| Q35113855 | Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies |
| Q35665722 | Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein |
| Q37548597 | Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans |
| Q33927239 | Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous |
| Q39579497 | Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity |
| Q36829966 | Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160. |
| Q36830124 | Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. |
| Q36796061 | Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. |
| Q39756449 | Glycosylation of immunodominant linear epitopes in the carboxy-terminal region of the caprine arthritis-encephalitis virus surface envelope enhances vaccine-induced type-specific and cross-reactive neutralizing antibody responses |
| Q35852493 | Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS Program. |
| Q35144796 | Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in viral replication |
| Q24627627 | Human immunodeficiency virus and acquired immunodeficiency syndrome: correlation but not causation |
| Q36690417 | Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity |
| Q33582665 | Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees |
| Q34338761 | Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells |
| Q36780203 | Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping |
| Q40109141 | Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system |
| Q69117601 | Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping |
| Q44247685 | Human monoclonal antibodies to HIV-1: cross-reactions with gag and env products |
| Q33880904 | Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain |
| Q36690500 | Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 |
| Q33567984 | Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization |
| Q36781270 | Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins |
| Q40015450 | Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein. |
| Q37634281 | Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition |
| Q55242221 | Mapping of IgG subclass and T-cell epitopes on HIV proteins by synthetic peptides. |
| Q37121446 | Method for detection of simian immunodeficiency virus neutralizing antibodies using a noncommercial antigen capture enzyme-linked immunosorbent assay. |
| Q36633402 | Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. |
| Q36687562 | Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody |
| Q35896178 | Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. |
| Q41172474 | Neutralizing antibodies and antigens in AIDS |
| Q30431941 | Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140 |
| Q45833259 | Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type I. |
| Q33720083 | Neutralizing antibodies modulate replication of simian immunodeficiency virus SIVmac in primary macaque macrophages |
| Q36881981 | Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. |
| Q24634681 | Pathogenesis of human immunodeficiency virus infection |
| Q39692591 | Pathogenesis of human immunodeficiency virus infection and prospects for control |
| Q45859829 | Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in infected individuals grouped according to CD4+ cell levels |
| Q33822379 | Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex |
| Q34313555 | Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers |
| Q34301897 | Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein |
| Q34097650 | Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein |
| Q34332284 | Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus |
| Q35853761 | Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent i |
| Q43449921 | Rates of amino acid change in the envelope protein correlate with pathogenicity of primate lentiviruses |
| Q36683893 | Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys |
| Q36360966 | Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells |
| Q40038277 | Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. |
| Q36684349 | Strain-specific neutralizing determinant in the transmembrane protein of simian immunodeficiency virus |
| Q35879339 | Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant |
| Q35835028 | Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. |
| Q36780046 | Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by a recombinant human adenovirus |
| Q36800188 | Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees |
| Q57607867 | Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses |
| Q36634149 | The "V3" domain is a determinant of simian immunodeficiency virus cell tropism. |
| Q40417980 | The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function |
| Q36704527 | The molecular structure of human antibodies specific for the human immunodeficiency virus |
| Q39579438 | The second extracellular loop of CXCR4 determines its function as a receptor for feline immunodeficiency virus. |
| Q36809662 | The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope |
| Q46361950 | The use of the clinical immunology laboratory |
| Q41562736 | Topogenic analysis of the human immunodeficiency virus type 1 envelope glycoprotein, gp160, in microsomal membranes |
| Q33560772 | Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides |
| Q40047131 | V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. |
| Q34101462 | Vaccine and antiviral strategies against infections caused by human immunodeficiency virus. |
| Q34201595 | Vertical Transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies |
| Q36783052 | Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation |
Search more.